Analysts: Buy Buffalo Wild Wings In the Low $90s and 3 More Research Notes to Check Out
Buffalo Wild Wings (NASDAQ:BWLD): RW Baird has taken Buffalo off its Focus Idea List due to outperformance, and the firm retains its Outperform rating and would be aggressive buyers in the low $90s. Price target is set at $95.
BioMarin (NASDAQ:BMRN): JPMorgan attributes yesterday’s weakness in shares of BioMarin to very high expectations for BMN 673 and a broader biotech sell-off, and uses the resulting weakness as a buying opportunity, as it believes that BMN 673 has shown clear anti-tumor activity.
Infinity Pharmaceuticals (NASDAQ:INFI): Following the company’s ASCO oral presentation of IPI-145 Phase I data in lymphoma patients, Piper Jaffray recommends buying shares of Infinity as they are ”too cheap to ignore,” and keeps an Overweight rating on the name with a $50 price target.
Six Flags (NYSE:SIX): The company will benefit from strong initial 2013 season pass sales and higher ticket prices, according to Wells Fargo, which lifted its price target range to $80-$83 from $71-$74. The firm notes that the stock has a high dividend yield and it keeps an Outperform rating on the shares.
Don’t Miss: Gun Control: Which Side Has More Passion?